The companies will produce the investigational stem cell-derived, fully differentiated insulin-producing islet cell therapy portfolio of Vertex for T1D. Credit: Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals and Lonza have entered a strategic partnership to establish a facility at Portsmouth, New Hampshire, US, to manufacture Vertex’s cell therapies for type 1 diabetes (T1D).

The companies will collaborate in the development and scale-up of the production of the cell therapy portfolio, and jointly fund the construction of the facility.

Related Company Profiles

View all

The 130,000ft² site will be run by Lonza and will create 300 new jobs. Construction will commence later this year.

The companies will produce the investigational stem cell-derived, fully differentiated insulin-producing islet cell therapy portfolio of Vertex for T1D patients.

The key focus will be on Vertex’s VX-880 and VX-264 programmes, which are currently in the clinical trial stage. VX-880 has shown clinical proof-of-concept while VX-264 is being analysed in a Phase I/II trial.

See Also:

A Vertex hypoimmune programme is also in the preclinical development stage.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vertex Pharmaceuticals CEO and president Reshma Kewalramani stated: “Vertex’s allogeneic, fully differentiated, insulin-producing islet cells, and the results from the Phase I/II VX-880 programme, represent a scientific breakthrough that offers the potential to transform the treatment of T1D.

“Establishing this strategic partnership with Lonza, a world-class manufacturing organisation, is a critical milestone in this journey and underscores our long-term commitment to patients with T1D.”

Last month, the company received US Food and Drug Administration approval for Kalydeco (ivacaftor) to treat children aged between one and four months with cystic fibrosis.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.